” NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 ” ” First regulatory filing for fruquintinib for use in...
Innovent First Dosed in Ph 3 (Neoshot) with Sintilimab for Colon Cancer
HONG KONG, Shanghai and FLORHAM Park, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:‹HCM, HKEX:‹13) (œHUTCHMED) today announces that it has completed enrollment of...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM:‹HCM; HKEX:‹13) today announces that the Center for Drug...
Synlogic has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for SYNB1934 to treat phenylketonuria (PKU), a rare inherited metabolic disease.